(lp0
S'Latest Pluristem Therapeutics Inc.  Lifted to Hold at Zacks Investment ... Petro Global News 24 - Jan 23, 2017 Zacks Investment Research upgraded shares of Pluristem Therapeutics Inc.  from a sell rating to a hold rating in a research report report published on Wednesday morning.Manitex International  Reaches $7.01 After 9.00% Down Move, Pluristem ... - HuronReport'
p1
aS"Pluristem Signs Term Sheet for $30 Million Equity Investment Agreement with a ... GlobeNewswire  - Oct 25, 2016 HAIFA, Israel, Oct. 25, 2016  -- Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced it has signed a term sheet for an investment of approximately&nbsp;...Israel's Pluristem to get $30m Chinese investment - The Times of Israel"
p2
aS'Pluristem Therapeutics - A Potential Beneficiary Of The 21st Century Cures Act Seeking Alpha - Dec 16, 2016 An accelerated development time frame is obviously huge news for a company like Pluristem since it greatly reduces the amount of cash burn required  and provides a leg-up on competition.'
p3
aS'FBR Capital Analyst Bullish on Pluristem Therapeutics Inc.  Following ... Smarter Analyst - Jul 11, 2016 FBR Capital analyst Vernon Bernardino weighed in on Pluristem Therapeutics Inc.  following the an announcement that the company plans to initiate a Phase I trial to investigate its PLX-R18 drug.'
p4
aS"Pluristem Announces Closing of Bought Offering and Underwriter's Exercise in ... GlobeNewswire  - Jan 25, 2017 HAIFA, Israel, Jan. 25, 2017  -- Pluristem Therapeutics Inc.   announced today that H.C."
p5
aS'Pluristem Announces Bought Deal Offering GlobeNewswire  - Jan 19, 2017 HAIFA, Israel, Jan. 19, 2017  -- Pluristem Therapeutics Inc.   announced today that it has entered into an underwriting agreement with H.C.Pluristem Therapeutics  Increases Bought Deal Offering of Common Stock ... - StreetInsider.com'
p6
aS'Pluristem Therapeutics: Questionable Ethics And Bucket Shop Coverage Seeking Alpha  - Feb 2, 2015 Pluristem Therapeutics Inc.  is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.'
p7
aS"Exclusive Interview With Pluristem Therapeutics Inc. President ... Market Exclusive - Nov 29, 2016 I was appointed Pluristem's President and Chief Operating Officer in 2014. Prior to that, I served as Pluristem's Chief Financial Officer and Secretary since 2006, and Executive Vice President since 2013. Before joining Pluristem, I was the Chief ..."
p8
aS'Will Pluristem Therapeutics Inc.  Succeed in CLI Where Sanofi SA ... Market Exclusive - Aug 11, 2016 Pluristem Therapeutics Inc.  has achieved just that, hitting for the cycle so to speak, with two accelerated approval pathways for its PLX-PAD placental cell treatment for critical limb ischemia .'
p9
aS'Next Weeks Broker Price Targets For Pluristem Therapeutics, Inc.  Fiscal Standard - 20 hours ago Stock market analysts and brokers have recently amended their target prices on shares of Pluristem Therapeutics, Inc. . According to the latest research reports released, 1 analyst has issued a rating of buy, 1 analysts outperform, 1 analysts ...'
p10
a.